A Phase 1 interventional study of Administration of UI111 and Administration of UIC202006 in Dyslipidemia, sponsored by Korea United Pharm. Inc.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Korea United Pharm. Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Dyslipidemias with a site in Korea, Republic of — 30 open to participants now, 39 under way, 5 of them phase 3. Dyslipidemias · Korea, Republic of.
Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, this one is the 100th largest by enrollment of the 124 interventional ones that give a count, is one of 14 that started in 2025, is one of 58 in phase 1, and was the 153rd registered.
1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →30 of the 155 studies in Dyslipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19–54 · Healthy volunteers
Yonsei University · Sites in Korea, Republic of
Ages 19–85
Sin Gon Kim · Sites in Korea, Republic of
Ages 70+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–100
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 100 across 987 interventional studies indexed under Dyslipidemias.
Median enrollment 80 across the 124 interventional studies, 5,000 across the 31 observational. Of the 99 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 155 have an industry lead sponsor. The 10 most frequent:
Korea United Pharm. Inc. is the lead sponsor of 22 studies on the registry; 6 are open to participants now.
Korea United Pharm. Inc. has 3 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
6 of the studies in Dyslipidemias with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07523971JW PharmaceuticalEfficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study | 2026-12 |
| NCT05365425Seoul National University Bundang HospitalCholine Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia | 2026-12-31 |
| NCT05365438Seoul National University Bundang HospitalAtmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia | 2026-12-31 |
| NCT06293417Korea University Anam HospitalTo Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM | 2027-02-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1 study to evaluate the safety and the pharmacokinetics of "UI111" and "UIC202006" in healthy adult volunteers under fed state conditions
- Open-label, randomized, single-dose, 2-sequence, 4-period, crossover design
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who agree that they and/or their spouse or partner will use medically acceptable methods (excluding hormonal contraceptives) from the first administration of the investigational product until 7 days after the last administration of the investigational product to prevent pregnancy, and who agree not to donate sperm or ova during this period.*
Exclusion Criteria:
For males: average alcohol consumption exceeding 21 standard drinks per week. For females: average alcohol consumption exceeding 14 standard drinks per week. (One standard drink = 50 mL of soju, 30 mL of spirits, or 250 mL of beer.) Smoking more than an average of 20 cigarettes per day. - Subjects who meet any of the following criteria: Known to the investigational product or any of its components. Hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
- Subjects with any of the following conditions: Severe hepatic impairment (e.g., biliary cirrhosis, active liver disease, or persistent unexplained elevations of transaminases exceeding 3 × the [ULN]).
Moderate to severe renal impairment (estimated [eGFR] \< 60 mL/min/1.73 m²).
A history of photoallergic or phototoxic reactions during treatment with fibrates or ketoprofen.
Gallbladder disease. Acute or chronic pancreatitis associated with hypertriglyceridemia. Myopathy; a history of rhabdomyolysis or myopathy associated with statins or fibrates; or a history of creatine phosphokinase (CPK) elevations ≥5 × ULN during previous statin therapy.
Interstitial lung disease. A history of pulmonary embolism. Severe myasthenia gravis or ocular myasthenia.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test
Drug: Administration of UI111
Reference
Drug: Administration of UIC202006
1cap, once a day
1cap, once a day
AUCt
Time frame: 0 to 12hours(Active ingredient A), 0 to 72hours(Active ingredient B)
Cmax
Time frame: 0 to 12hours(Active ingredient A), 0 to 72hours(Active ingredient B)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Mar 2025, 0 months.
Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 0 months is below that.
Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.